JP7601852B2 - ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体 - Google Patents

４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体 Download PDF

Info

Publication number
JP7601852B2
JP7601852B2 JP2022504198A JP2022504198A JP7601852B2 JP 7601852 B2 JP7601852 B2 JP 7601852B2 JP 2022504198 A JP2022504198 A JP 2022504198A JP 2022504198 A JP2022504198 A JP 2022504198A JP 7601852 B2 JP7601852 B2 JP 7601852B2
Authority
JP
Japan
Prior art keywords
methyl
het
pyridin
pyrimidin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542072A5 (https=
JP2022542072A (ja
Inventor
ドルシュ，ディーター
ブルム，アンドレアス
ブクスタラー，ハンス－ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2022542072A publication Critical patent/JP2022542072A/ja
Publication of JP2022542072A5 publication Critical patent/JP2022542072A5/ja
Priority to JP2024212157A priority Critical patent/JP7730407B2/ja
Application granted granted Critical
Publication of JP7601852B2 publication Critical patent/JP7601852B2/ja
Priority to JP2025135307A priority patent/JP2025186243A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022504198A 2019-07-24 2020-07-22 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体 Active JP7601852B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024212157A JP7730407B2 (ja) 2019-07-24 2024-12-05 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体
JP2025135307A JP2025186243A (ja) 2019-07-24 2025-08-15 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188031.9 2019-07-24
EP19188031 2019-07-24
PCT/EP2020/070616 WO2021013864A1 (en) 2019-07-24 2020-07-22 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024212157A Division JP7730407B2 (ja) 2019-07-24 2024-12-05 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2022542072A JP2022542072A (ja) 2022-09-29
JP2022542072A5 JP2022542072A5 (https=) 2023-07-31
JP7601852B2 true JP7601852B2 (ja) 2024-12-17

Family

ID=67438678

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022504198A Active JP7601852B2 (ja) 2019-07-24 2020-07-22 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体
JP2024212157A Active JP7730407B2 (ja) 2019-07-24 2024-12-05 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体
JP2025135307A Pending JP2025186243A (ja) 2019-07-24 2025-08-15 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024212157A Active JP7730407B2 (ja) 2019-07-24 2024-12-05 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体
JP2025135307A Pending JP2025186243A (ja) 2019-07-24 2025-08-15 ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体

Country Status (13)

Country Link
US (2) US20220267320A1 (https=)
EP (1) EP4003992A1 (https=)
JP (3) JP7601852B2 (https=)
KR (2) KR20250174707A (https=)
CN (2) CN118955500A (https=)
AR (1) AR119461A1 (https=)
AU (2) AU2020318710B2 (https=)
BR (1) BR112022001158A2 (https=)
CA (1) CA3148227A1 (https=)
IL (1) IL289953B2 (https=)
MX (1) MX2022000794A (https=)
TW (1) TWI868186B (https=)
WO (1) WO2021013864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN120379972A (zh) * 2022-12-20 2025-07-25 深圳湾实验室 一种靶向usp1的小分子抑制剂及其应用
WO2025248485A1 (en) 2024-05-31 2025-12-04 Idrx, Inc. Pharmaceutical compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522143A (ja) 2003-04-04 2006-09-28 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての新規化合物および組成物
WO2008081914A1 (ja) 2006-12-28 2008-07-10 Banyu Pharmaceutical Co., Ltd. Ｐｌｋ１阻害剤としての新規アミノピリミジン誘導体
JP2011528040A (ja) 2008-07-14 2011-11-10 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤
JP2016529292A (ja) 2013-08-30 2016-09-23 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522143A (ja) 2003-04-04 2006-09-28 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての新規化合物および組成物
WO2008081914A1 (ja) 2006-12-28 2008-07-10 Banyu Pharmaceutical Co., Ltd. Ｐｌｋ１阻害剤としての新規アミノピリミジン誘導体
JP2011528040A (ja) 2008-07-14 2011-11-10 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤
JP2016529292A (ja) 2013-08-30 2016-09-23 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤

Also Published As

Publication number Publication date
IL289953B1 (en) 2024-11-01
AU2020318710B2 (en) 2025-11-20
KR20220041133A (ko) 2022-03-31
BR112022001158A2 (pt) 2022-05-17
EP4003992A1 (en) 2022-06-01
JP2025186243A (ja) 2025-12-23
KR102894509B1 (ko) 2025-12-02
US20260109697A1 (en) 2026-04-23
IL289953B2 (en) 2025-03-01
WO2021013864A1 (en) 2021-01-28
TWI868186B (zh) 2025-01-01
JP7730407B2 (ja) 2025-08-27
KR20250174707A (ko) 2025-12-12
AU2026200481A1 (en) 2026-02-12
CN118955500A (zh) 2024-11-15
TW202118762A (zh) 2021-05-16
MX2022000794A (es) 2022-02-16
US20220267320A1 (en) 2022-08-25
AR119461A1 (es) 2021-12-22
IL289953A (en) 2022-03-01
CA3148227A1 (en) 2021-01-28
AU2020318710A1 (en) 2022-03-10
CN114174293B (zh) 2024-08-06
JP2022542072A (ja) 2022-09-29
CN114174293A (zh) 2022-03-11
JP2025060626A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
IL323371A (en) Broadly neutralizing antibodies against the AIDS virus
JP7730407B2 (ja) ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体
JP7744540B2 (ja) がんなどの疾患の処置のためのインダゾリル－イソオキサゾール誘導体
RU2822388C2 (ru) 4-(ИМИДАЗО[1,2-а]ПИРИДИН-3-ИЛ)-ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ
RU2836662C2 (ru) Индазолилизоксазольные производные для лечения заболеваний, таких как злокачественное новообразование
HK40122817A (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
HK40065185A (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241003

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241205

R150 Certificate of patent or registration of utility model

Ref document number: 7601852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150